title: DAD1- and DAD2-like agonist effects on motor activity of C57 mice: differences compared to rats.
abstract: Studies on rats indicate that DAD1- and DAD2-like agonists produce a biphasic action on motor activity, with low doses reducing activity below control levels, and higher doses initially reducing, then elevating, activity for a prolonged period. Although some of the reported effects of DAD1- and DAD2-like receptor agonists on motor activity of mice are consistent with their effects on rats, the possibility of species differences is also apparent. In the current study the effects of DAD1- and DAD2-like agonists on motor activity of C57BL/6 (C57) mice were determined to establish species consistencies and differences with respect to their effects on rats. The partial DAD1-like agonist SKF 38393 reduced the activity of C57 mice at low doses and elevated activity above control levels at higher doses, if the mice were thoroughly habituated to the test chamber. The full DAD1 agonist SKF 82958 also increased the activity of C57 mice, and along with the SKF 38393 results indicates a response to DAD1 receptor stimulation similar to that reported for rats. In contrast to the species similarity in response to DAD1 stimulation, the DAD2-like agonist quinpirole produced only a dose-responsive monotonic reduction in the activity of C57 mice, whether the animals were nonhabituated or well-habituated to the testing environment, male or female, young or mid-aged, injected intraperitoneally (i.p.) or subcutaneously (s.c.), and with either low or high doses. This apparent species difference in response to quinpirole might reflect distinguishable functional properties of the DA subreceptor systems.
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston 29425-0742, USA.
authors.forename: J P
authors.initials: JP
authors.lastname: Halberda
authors.forename: L D
authors.initials: LD
authors.lastname: Middaugh
authors.forename: B E
authors.initials: BE
authors.lastname: Gard
authors.forename: B P
authors.initials: BP
authors.lastname: Jackson
mesh_terms: D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology*; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology*; D018491:Dopamine Agonists / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects*; D051381:Rats; D017447:Receptors, Dopamine D1 / Q000819:agonists*; D017448:Receptors, Dopamine D2 / Q000819:agonists*
chemical_list: D001552:Benzazepines; D018491:Dopamine Agonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; C071262:SK&F 82958